Topics

German drug assessment body not convinced by Bayer's cancer drug Vitrakvi

10:00 EST 16 Jan 2020 | Reuters

Germany's drug assessment body said that data provided by Bayer on its precision cancer drug Vitrakvi did not provide clear enough evidence of benefits, in a setback to the drugmaker in its home market.

Original Article: German drug assessment body not convinced by Bayer's cancer drug Vitrakvi

NEXT ARTICLE

More From BioPortfolio on "German drug assessment body not convinced by Bayer's cancer drug Vitrakvi"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...